One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Ambrx Biopharma Inc - ADR before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Ambrx Biopharma Inc - ADR’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Ambrx Biopharma Inc - ADR’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Ambrx Biopharma Inc - ADR (AMAM)

Before we jump into Ambrx Biopharma Inc - ADR’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Ambrx Biopharma Inc. is a clinical-stage biologics company. It is focused on discovering and developing a novel class of engineered precision biologics, using its expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids (SAAs), into proteins within living cells. Its product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation, offering potential safety and benefits to treat patients across multiple therapeutic areas. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as antibody-drug conjugates (ADCs), immuno-oncology conjugate, bispecific antibodies, PEGylated peptides, modified cytokines and immuno-stimulating antibody conjugates. Its lead ADC product candidates in clinical development: ARX788 and ARX517. ARX517 is an anti-prostate-specific membrane antigen.

Want to learn more about Ambrx Biopharma Inc - ADR’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ambrx Biopharma Inc - ADR. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Ambrx Biopharma Inc - ADR’s Stock Price as of Market Close

As of September 11, 2023, 4:00 PM CST, Ambrx Biopharma Inc - ADR’s stock price was $11.64.

Ambrx Biopharma Inc - ADR is down 4.67% from its previous closing price of $12.21.

During the last market session, Ambrx Biopharma Inc - ADR’s stock traded between $12.10 and $12.79. Currently, there are 55.90 million shares of Ambrx Biopharma Inc - ADR stock available for purchase.

Unfortunately, Ambrx Biopharma Inc - ADR’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Ambrx Biopharma Inc - ADR Stock Price History

Ambrx Biopharma Inc - ADR’s (AMAM) price is currently down 17.56% so far this month.

During the month of September, Ambrx Biopharma Inc - ADR’s stock price has reached a high of $15.10 and a low of $11.61.

Over the last year, Ambrx Biopharma Inc - ADR has hit prices as high as $16.86 and as low as $0.38. Year to date, Ambrx Biopharma Inc - ADR’s stock is up 28.9%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ambrx Biopharma Inc - ADR Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 08, 2023, there were 0 analysts who downgraded Ambrx Biopharma Inc - ADR’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Ambrx Biopharma Inc - ADR’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ambrx Biopharma Inc - ADR (AMAM) by visiting AAII Stock Evaluator.

Relative Price Strength of Ambrx Biopharma Inc - ADR

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of September 08, 2023, Ambrx Biopharma Inc - ADR has a weighted four-quarter relative price strength of 385.74%, which translates to a Momentum Score of 100 and is considered to be Very Strong.

Want to learn more about how Ambrx Biopharma Inc - ADR is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ambrx Biopharma Inc - ADR Stock Price: Bottom Line

As of September 11, 2023, Ambrx Biopharma Inc - ADR’s stock price is $11.64, which is down 4.67% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Ambrx Biopharma Inc - ADR’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.